Novartis stays focused
No big deals needed, executives insist, but a pipeline purge continues and analysts warn of a growth problem.
Boehringer signals intent in obesity
Obesity is biopharma’s hottest ticket, and Boehringer Ingelheim wants a seat at the show.
